In-gel digestion coupled with mass spectrometry (GeLC-MS/MS)-based salivary proteomic profiling of canine oral tumors
Authors:
- Sekkarin PloypetchSPSekkarin Ploypetch
- Sittiruk RoytrakulSRSittiruk Roytrakul
- Narumon PhaonakropNPNarumon Phaonakrop
- Suthathip KittisenachaiSKSuthathip Kittisenachai
- Kantinan LeetanasaksakulKLKantinan Leetanasaksakul
- Sirinun PisamaiSPSirinun Pisamai
- Chanin KalpravidhCKChanin Kalpravidh
- Anudep RungsipipatARAnudep Rungsipipat
- Gunnaporn SuriyapholGSGunnaporn Suriyaphol
Open Access
- 14 September 2020
- journal article
- research article
- Published by Springer Nature in BMC Veterinary Research
- Vol. 16 (1) , 1-17
Abstract
Background: Various types of oral tumors, either benign or malignant, are commonly found in dogs. Since saliva directly contacts the tumors and saliva collection is non-invasive, easily accessible and cost effective, salivary biomarkers are practical to be used for the diagnosis and/or prognosis of these diseases. However, there is limited knowledge of protein expression in saliva for canine oral tumors. The present study aimed to investigate novel biomarkers from the salivary proteome of dogs with early- and late-stage oral melanoma (EOM and LOM, respectively), oral squamous cell carcinoma (OSCC), benign oral tumors (BN), and periodontitis and healthy controls (CP), using an in-gel digestion coupled with mass spectrometry (GeLC-MS/MS). The relationships between protein candidates and chemotherapy drugs were explored and the expression of potential biomarkers in saliva and tissues was verified by western blot analysis. Results: For saliva samples, increased expression of protein tyrosine phosphatase non-receptor type 5 (PTPN5) was shown in all tumor groups compared with the CP group. Marked expression of PTPN5 was also observed in LOM and OSCC compared with that in BN and EOM. In addition, tumor protein p53 (p53), which appeared in the PTPN5–drug interactions, was exhibited to be expressed in all tumor groups compared with that in the CP group. For tissue samples, increased expression of p53 was shown in LOM compared with the control group. Conclusion: PTPN5 and p53 were proposed to be potential salivary biomarkers of canine oral tumors.Keywords
Funding Information
- TRF Research Career Development Grant (RSA5980053)
- the 100th Anniversary of Chulalongkorn University for a Doctoral Scholarship
- the 90th Anniversary of Chulalongkorn University Scholarship
- an Overseas Research Experience Scholarship for Graduate Student
This publication has 49 references indexed in Scilit:
- Disruptive TP53 Mutation Is Associated with Aggressive Disease Characteristics in an Orthotopic Murine Model of Oral Tongue CancerClinical Cancer Research, 2011
- Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival studyHead & Neck Oncology, 2011
- Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancerAnalytica Chimica Acta, 2010
- Comparative Human Salivary and Plasma ProteomesJournal of Dental Research, 2010
- Oral malignant melanomas and other head and neck neoplasms in Danish dogs - data from the Danish Veterinary Cancer RegistryActa Veterinaria Scandinavica, 2009
- Salivary Proteomics for Oral Cancer Biomarker DiscoveryClinical Cancer Research, 2008
- SHP2 is up‐regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesisHistopathology, 2008
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2007
- Differential expression analysis of Escherichia coli proteins using a novel software for relative quantitation of LC‐MS/MS dataProteomics, 2006
- Prognostic significance of p53 mutations in colon cancer at the population levelInternational Journal of Cancer, 2002